RecruitingHematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis
Q702 for the Treatment of Patients With Hematologic Malignancies
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ PRE-REGISTRATION: Age ≥ 18 years
- ✓ PRE-REGISTRATION: Not eligible for or have failed therapies with established benefits, at the discretion of the treating physician
- ✓ PRE-REGISTRATION: Patients must meet one of the following criteria:
- ✓ Relapsed/refractory patients with Erdheim-Chester disease, Langerhans histiocytosis, histiocytic sarcoma, or other malignant histiocytosis without activating alterations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) or Mitogen-activated protein kinase kinase (MAP2K) oncogenes who have progressed after first line of therapy.
- ✓ Note: Relapsed is defined as a relapse that occurred after having a response to the last therapy at any point during the treatment. Refractory is no response (stable disease or progressive disease while on therapy) to a given treatment at least after 1 month of being on the given treatment.
- ✓ Newly diagnosed patients with Rosai-Dorfman disease without activating alterations in MAP2K oncogenes.
- ✓ Relapsed/refractory patients with Rosai-Dorfman disease and an activating mitogen-activated protein kinase (MAPK) pathway alteration who have failed prior treatment with cobimetinib.
- ✓ Relapsed/refractory patients with Erdheim-Chester disease or Langerhans histiocytosis who have received vemurafenib for BRAF V600E mutated disease or cobimetinib for disease with activating MAP2K alterations.
You may not qualify if…
- ✕ PRE-REGISTRATION: Myeloproliferative neoplasm (MPN) patients with known active CNS metastases and/or carcinomatous meningitis.
- ✕ Note: Histiocytosis and lymphoma patients who are on steroids are allowed to enroll
- ✕ REGISTRATION: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effect on the developing fetus and newborn are unknown:
- ✕ Pregnant persons
- ✕ Nursing persons
- ✕ Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception
- ✕ REGISTRATION: New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure ≤ 6 months prior to registration
- ✕ REGISTRATION: Corrected QT interval (using Fridericia's correction formula) (QTcF) of \> 470 msec
Where it's recruiting
Source: ClinicalTrials.gov · NCT06712810 · last updated 2025-10-10